Research from Around the world
Lupus News
In an effort to understand the origin of systemic lupus erythematosus and why some patients present with more severe disease than others, Johns Hopkins Medicine researchers say they have identified a type of autoantibody that may worsen the condition and have also found how these autoantibodies originate (Anti-DNA antibodies are a hallmark of patients with SLE.).
A new study has found promise in a compound which blocks signals from special receptors in the body thought to be involved in the autoimmune response. More specifically, these receptors are proteins which are designed to detect viral RNA, but mount an autoimmune response when they mistake the body’s own RNA as a threat.
The skin is the second most affected organ in lupus patients. Cutaneous involvement occurs in approximately 80% of patients with systemic lupus.
Interaction between the host and skin microorganism is a complex process. There are few studies on the diversity of skin microbes in SLE patients. The new study aims to explore the relationship between skin microorganisms and SLE
Hydroxychloroquine is widely used to treat certain viral and rheumatic diseases including systemic lupus erythematosus. Cardiac arrhythmia is an important safety issue with hydroxychloroquine. The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with systemic lupus erythematosus.
